George Spencer-Green, MD, MS, has been appointed chief medical officer, Taiwan Liposome Company, Ltd. Dr. Spencer-Green will serve as a member of the TLC management team and guide the company in its clinical and regulatory activities.

Dr. Spencer-Green has more than three decades of clinical medicine and drug development experience. As the prior vice president and clinical head of Pfizer’s biosimilars development program, he led the team that designed and initiated clinical development plans from Phase I to Phase III for five assets. Prior to Pfizer, he served as the senior medical director at Vertex Pharmaceuticals, where he led the design and execution of clinical development programs in rheumatoid arthritis and cystic fibrosis. Prior to Vertex, he was the global medical director at Abbott Laboratories, and was the clinical lead for the rheumatoid arthritis registration and long-term extension programs for Humira.

“We are thrilled to welcome Dr. Spencer-Green to the TLC family and look forward to his capable leadership as we transition into a late-stage company with the advancement of our osteoarthritis program through the clinic,” said TLC president George Yeh. “Dr. Spencer-Green will play an integral role in the clinical development strategies of all our programs. I am confident that his expertise will help guide the advancement of our clinical trial designs and executions.”